Study With QR-504a to Evaluate Safety, Tolerability & Corneal Endothelium Molecular Biomarker(s) in Subjects With FECD3
- Conditions
- Fuchs Endothelial Corneal DystrophyLRSFECD3Corneal DiseasesDescemet's Membrane Disorder
- Interventions
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- ProQR Therapeutics
- Registration Number
- NCT05052554
- Locations
- 🇬🇧
Moorfields Eye Hospital, NIHR Clinical Research Facility, London, United Kingdom
An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene.
- Conditions
- Leber Congenital AmaurosisEye Disorders CongenitalRetinal DegenerationRetinal DystrophiesBlindnessSensation DisordersEye DiseasesRetinal DiseaseLeber Congenital Amaurosis 10Vision Disorders
- Interventions
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2022-03-25
- Lead Sponsor
- ProQR Therapeutics
- Target Recruit Count
- 15
- Registration Number
- NCT04855045
- Locations
- 🇳🇱
Amsterdam University Medica Center - Locatie AMC, Amsterdam, Netherlands
🇩🇪University of Tübingen - Institute for Ophthalmic Research, Tübingen, Germany
🇮🇹Eye Clinic University of Campania Liugi Vanvitelli, Naples, Italy
A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene
- Conditions
- Autosomal Dominant Retinitis PigmentosaEye Diseases, HereditaryRetinitisEye DiseasesRetinal DystrophiesRetinal DiseaseVision TunnelVision Disorders
- Interventions
- Other: Sham procedure
- First Posted Date
- 2019-10-11
- Last Posted Date
- 2022-05-06
- Lead Sponsor
- ProQR Therapeutics
- Target Recruit Count
- 11
- Registration Number
- NCT04123626
- Locations
- 🇺🇸
Retina Foundation of the Southwest, Dallas, Texas, United States
🇺🇸Casey Eye Institute, OHSU, Portland, Oregon, United States
🇺🇸Sue Anschutz-Rogers Eye Center, University of Colorado - Dept. of Ophthalmology, Aurora, Colorado, United States
A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)
- Conditions
- Neurologic ManifestationsBlindnessLeber Congenital AmaurosisEye DiseasesEye Disorders CongenitalVision DisordersLeber Congenital Amaurosis 10Sensation DisordersRetinal DiseaseEye Diseases, Hereditary
- Interventions
- Other: Sham
- First Posted Date
- 2019-04-12
- Last Posted Date
- 2022-03-17
- Lead Sponsor
- ProQR Therapeutics
- Target Recruit Count
- 36
- Registration Number
- NCT03913143
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇧🇪Universitair Ziekenhuis Gent (UZ), Ghent, Belgium
🇬🇧Moorfields Eye Hospital - NHS Foundation Trust, London, United Kingdom
Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene
- Conditions
- Retinitis PigmentosaEye Disorders CongenitalVision DisordersUsher Syndrome Type 2Deaf BlindRetinal DiseaseEye DiseasesEye Diseases, Hereditary
- Interventions
- Other: Sham-procedure (dose cohort 1&2 only)
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- ProQR Therapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT03780257
- Locations
- 🇺🇸
University of Michigan, Kellogg Eye Center, Ann Arbor, Michigan, United States
🇫🇷Hôpital Gui de Chauliac - CHRU de Montpellier - Maladies Sensorielles Génétique, Montpellier, France
🇺🇸Retina Foundation of the Southwest, Dallas, Texas, United States
Exploratory Study to Evaluate QR-010 in Subjects With Cystic Fibrosis ΔF508 CFTR Mutation
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2020-09-24
- Lead Sponsor
- ProQR Therapeutics
- Target Recruit Count
- 18
- Registration Number
- NCT02564354
- Locations
- 🇺🇸
Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States
🇧🇪U.Z. Leuven, Leuven, Belgium
🇺🇸National Jewish Health, Denver, Colorado, United States
Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients
- First Posted Date
- 2015-08-26
- Last Posted Date
- 2019-02-06
- Lead Sponsor
- ProQR Therapeutics
- Target Recruit Count
- 70
- Registration Number
- NCT02532764
- Locations
- 🇺🇸
University of Southern California USC - Keck School of Medicine, Los Angeles, California, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Northwestern University, Chicago, Illinois, United States